What is Acgt?
ACGT is a distinguished provider of DNA sequencing and molecular biology services, boasting over three decades of specialized expertise. The company offers a comprehensive suite of applications, including viral genome sequence analysis, pathogen detection, and microbiome profiling. Their core services encompass Sanger sequencing, next-generation sequencing, and SNP genotyping, all delivered with a commitment to high-quality results and rapid turnaround times. ACGT is recognized as a trusted partner for clients operating within research and regulatory environments, further enhanced by their dedication to customer service and quality assurance. They also provide complimentary trials to prospective users, allowing them to experience the caliber of their data and services firsthand.
How much funding has Acgt raised?
Acgt has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Acgt?
The recent major strategic investment, as part of ACGT's large-scale late-stage funding, signals a strong confidence from stakeholders in the company's market position and future trajectory. This capital is expected to fuel strategic initiatives, potentially including the expansion of service offerings, enhancement of technological capabilities, or broader market penetration. ACGT's established expertise in DNA sequencing and molecular biology, coupled with this financial backing, suggests a strategic focus on solidifying its leadership in areas such as pathogen detection and microbiome analysis, while continuing to serve its research and regulatory client base.
See full Acgt company page
